6.
Fanin M, Angelini C
. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002; 28(6):461-70.
DOI: 10.1046/j.1365-2990.2002.00417.x.
View
7.
Bansal D, Campbell K
. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol. 2004; 14(4):206-13.
DOI: 10.1016/j.tcb.2004.03.001.
View
8.
Villar-Quiles R, von der Hagen M, Metay C, Gonzalez V, Donkervoort S, Bertini E
. The clinical, histologic, and genotypic spectrum of -related myopathy: A case series. Neurology. 2020; 95(11):e1512-e1527.
PMC: 7713742.
DOI: 10.1212/WNL.0000000000010327.
View
9.
Bhatia A, Mobley B, Cogan J, Koziura M, Brokamp E, Phillips J
. Magnetic Resonance Imaging characteristics in case of TOR1AIP1 muscular dystrophy. Clin Imaging. 2019; 58:108-113.
PMC: 6893088.
DOI: 10.1016/j.clinimag.2019.06.010.
View
10.
Seror P, Krahn M, Laforet P, Leturcq F, Maisonobe T
. Complete fatty degeneration of lumbar erector spinae muscles caused by a primary dysferlinopathy. Muscle Nerve. 2007; 37(3):410-4.
DOI: 10.1002/mus.20910.
View
11.
Scalco R, Lorenzoni P, Lynch D, Martins W, Jungbluth H, Quinlivan R
. Polymyositis without Beneficial Response to Steroid Therapy: Should Miyoshi Myopathy be a Differential Diagnosis?. Am J Case Rep. 2017; 18:17-21.
PMC: 5228759.
DOI: 10.12659/ajcr.900970.
View
12.
Rowin J, Meriggioli M, Cochran E, Sanders D
. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord. 1999; 9(6-7):417-20.
DOI: 10.1016/s0960-8966(99)00041-3.
View
13.
Angelini C, Peterle E, Gaiani A, Bortolussi L, Borsato C
. Dysferlinopathy course and sportive activity: clues for possible treatment. Acta Myol. 2011; 30(2):127-32.
PMC: 3235880.
View
14.
Harris E, Bladen C, Mayhew A, James M, Bettinson K, Moore U
. The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2016; 2(4):e89.
PMC: 4994875.
DOI: 10.1212/NXG.0000000000000089.
View
15.
Dubowitz V
. 50th ENMC International Workshop: congenital muscular dystrophy. 28 February 1997 to 2 March 1997, Naarden, The Netherlands. Neuromuscul Disord. 2000; 7(8):539-47.
View
16.
Bardakov S, Tsargush V, Carlier P, Nikitin S, Kurbatov S, Titova A
. Magnetic resonance imaging pattern variability in dysferlinopathy. Acta Myol. 2022; 40(4):158-171.
PMC: 8744010.
DOI: 10.36185/2532-1900-059.
View
17.
Ferreiro A, Quijano-Roy S, Pichereau C, Moghadaszadeh B, Goemans N, Bonnemann C
. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet. 2002; 71(4):739-49.
PMC: 378532.
DOI: 10.1086/342719.
View
18.
Amato A, Brown Jr R
. Dysferlinopathies. Handb Clin Neurol. 2011; 101:111-8.
DOI: 10.1016/B978-0-08-045031-5.00007-4.
View
19.
Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y
. Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype. Neurology. 2003; 60(11):1799-804.
DOI: 10.1212/01.wnl.0000068333.43005.12.
View
20.
Ceccon G, Lehmann H, Neuen-Jacob E, Meng G, Fink G, Wunderlich G
. ["Therapy-resistant polymyositis" - is the diagnosis correct?]. Z Rheumatol. 2017; 76(7):640-643.
DOI: 10.1007/s00393-017-0326-0.
View